share_log

Frank T. Watkins Sells 3,000 Shares of ShockWave Medical, Inc. (NASDAQ:SWAV) Stock

Frank T. Watkins Sells 3,000 Shares of ShockWave Medical, Inc. (NASDAQ:SWAV) Stock

弗兰克·T·沃特金斯出售3,000股冲击波医疗公司(纳斯达克代码:SWAV)股票
Defense World ·  2022/09/23 05:12

ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) Director Frank T. Watkins sold 3,000 shares of the firm's stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $290.09, for a total transaction of $870,270.00. Following the completion of the sale, the director now owns 9,796 shares of the company's stock, valued at $2,841,721.64. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

冲击波医疗公司(纳斯达克代码:SWAVGET评级)董事弗兰克·T·沃特金斯在一笔日期为9月20日(星期二)的交易中出售了3,000股该公司股票。这些股票以290.09美元的平均价格出售,总成交金额为870,270.00美元。出售完成后,董事现在拥有9,796股该公司股票,价值2,841,721.64美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接.

ShockWave Medical Stock Down 9.1 %

冲击波医疗类股下跌9.1%

Shares of SWAV opened at $258.84 on Friday. The firm's 50 day moving average is $263.66 and its 200-day moving average is $208.21. The stock has a market capitalization of $9.26 billion, a PE ratio of 177.29 and a beta of 1.06. The company has a current ratio of 5.32, a quick ratio of 4.41 and a debt-to-equity ratio of 0.02. ShockWave Medical, Inc. has a 12 month low of $113.36 and a 12 month high of $314.90.

上周五,西南航空的股价开盘报258.84美元。该公司的50日移动均线切入位在263.66美元,200日移动均线切入位在208.21美元。该股市值为92.6亿美元,市盈率为177.29,贝塔系数为1.06.该公司的流动比率为5.32,速动比率为4.41,债务权益比率为0.02。Shockwave Medical,Inc.的12个月低点为113.36美元,12个月高位为314.90美元。

Get
到达
ShockWave Medical
冲击波医疗
alerts:
警报:

ShockWave Medical (NASDAQ:SWAV – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.25. The business had revenue of $120.70 million for the quarter, compared to analysts' expectations of $107.51 million. ShockWave Medical had a net margin of 15.11% and a return on equity of 21.25%. The firm's quarterly revenue was up 115.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.01) earnings per share. Equities research analysts forecast that ShockWave Medical, Inc. will post 2.57 EPS for the current year.

冲击波医疗(纳斯达克:SWAV-GET评级)上一次公布季度收益数据是在8月8日(星期一)。该公司公布本季度每股收益(EPS)为0.68美元,高于分析师普遍预期的0.43美元和0.25美元。该业务当季营收为1.207亿美元,高于分析师预期的1.0751亿美元。Shockwave Medical的净利润率为15.11%,股本回报率为21.25%。该公司的季度收入与去年同期相比增长了115.5%。去年同期,该公司公布的每股收益为0.01美元。股票研究分析师预测,Shockwave Medical,Inc.本年度每股收益将达到2.57美元。

Analysts Set New Price Targets

分析师设定新的价格目标

Several brokerages have issued reports on SWAV. Oppenheimer downgraded shares of ShockWave Medical from a "market perform" rating to an "underperform" rating and set a $165.00 price objective for the company. in a research report on Tuesday, September 6th. Morgan Stanley raised their price objective on shares of ShockWave Medical from $201.00 to $255.00 and gave the stock an "equal weight" rating in a research report on Tuesday, August 9th. Piper Sandler raised their price objective on shares of ShockWave Medical from $278.00 to $338.00 and gave the stock an "overweight" rating in a research report on Monday, August 29th. Wells Fargo & Company raised their price objective on shares of ShockWave Medical from $176.00 to $255.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 9th. Finally, Canaccord Genuity Group raised their price objective on shares of ShockWave Medical from $232.00 to $256.00 and gave the stock a "buy" rating in a research report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, ShockWave Medical presently has a consensus rating of "Moderate Buy" and an average price target of $246.50.
几家券商已经发布了关于SWAV的报告。奥本海默将Shockwave Medical的股票评级从“市场表现”下调至“表现不佳”,并为该公司设定了165.00美元的目标价。在9月6日星期二的一份研究报告中。8月9日,摩根士丹利在一份研究报告中将冲击波医疗的股票目标价从201.00美元上调至255.00美元,并给予该股“同等权重”的评级。8月29日,派珀·桑德勒在一份研究报告中将Shockwave Medical的股票目标价从278.00美元上调至338.00美元,并给予该股“增持”评级。富国银行将Shockwave Medical的股票目标价从176.00美元上调至255.00美元,并在8月9日(星期二)的一份研究报告中给予该股“增持”评级。最后,Cancord Genuity Group在8月9日(星期二)的一份研究报告中将Shockwave Medical的股票目标价从232.00美元上调至256.00美元,并给予该股“买入”评级。一名投资分析师对该股的评级为卖出,一名分析师给出了持有评级,七名分析师给出了该公司股票的买入评级。根据MarketBeat的数据,Shockwave Medical目前的共识评级为“中等买入”,平均目标价为246.50美元。

Institutional Inflows and Outflows

机构资金流入和流出

Hedge funds have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. increased its stake in ShockWave Medical by 104.9% in the fourth quarter. Rockefeller Capital Management L.P. now owns 166 shares of the company's stock valued at $29,000 after acquiring an additional 85 shares during the last quarter. CWM LLC grew its stake in shares of ShockWave Medical by 219.7% during the second quarter. CWM LLC now owns 195 shares of the company's stock worth $37,000 after buying an additional 134 shares during the last quarter. AdvisorShares Investments LLC bought a new stake in shares of ShockWave Medical during the first quarter worth $40,000. PenderFund Capital Management Ltd. bought a new stake in shares of ShockWave Medical during the first quarter worth $41,000. Finally, First Horizon Advisors Inc. grew its stake in shares of ShockWave Medical by 3,666.7% during the second quarter. First Horizon Advisors Inc. now owns 226 shares of the company's stock worth $43,000 after buying an additional 220 shares during the last quarter. 95.40% of the stock is owned by institutional investors.

对冲基金最近增持或减持了该公司的股份。洛克菲勒资本管理公司在第四季度增持了Shockwave Medical的股份104.9%。洛克菲勒资本管理公司在上个季度增持了85股股票后,现在拥有166股该公司股票,价值2.9万美元。第二季度,Cwm LLC在Shockwave Medical的持股增加了219.7%。Cwm LLC现在持有195股该公司股票,价值3.7万美元,在上个季度又购买了134股。AdvisorShares Investments LLC在第一季度购买了ShockWave Medical价值4万美元的新股。PenderFund Capital Management Ltd.在第一季度购买了Shockwave Medical价值41,000美元的新股。最后,First Horizon Advisors Inc.在第二季度增持了Shockwave Medical的股份3,666.7%。First Horizon Advisors Inc.现在持有226股该公司股票,价值43,000美元,该公司在上个季度又购买了220股。95.40%的股票由机构投资者持有。

About ShockWave Medical

关于冲击波医疗

(Get Rating)

(获取评级)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Shockwave Medical,Inc.是一家医疗设备公司,致力于开发和商业化血管内碎石技术,用于治疗全球外周血管、冠状动脉和心脏瓣膜疾病患者的钙化斑块。该公司提供用于治疗膝关节以上外周动脉疾病(PAD)的M5导管;用于治疗冠状动脉疾病的C2导管;以及用于治疗膝盖以下PAD的S4导管。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
  • What Steelcase's Earnings Say About the Return to the Office?
  • The Institutions Hold On To Darden Restaurants International
  • Is The Golden Age Of Homebuilding Already Over?
  • These 3 Big Dividend Payers Also Boast Strong Price Growth
  • Natural Gas Prices Continue To Rally, These Stocks Should Benefit
  • 免费获取StockNews.com关于Shockwave Medical(SWAV)的研究报告
  • 斯蒂尔凯斯的收益说明了他重返办公室的原因吗?
  • 这些机构持有达顿餐饮国际公司的股份
  • 住房建设的黄金时代已经结束了吗?
  • 这三大股利支付者也拥有强劲的价格增长
  • 天然气价格继续回升,这些股票应该会受益

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受《冲击波医学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ShockWave Medical和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发